Основная статистика
| CIK | 1611746 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to SciSparc Ltd.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2025 (Report No. 5) Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address o |
|
| August 28, 2025 |
SciSparc: AutoMax’s Shareholders Approve Merger with SciSparc Exhibit 99.2 SciSparc: AutoMax’s Shareholders Approve Merger with SciSparc TEL AVIV, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that AutoMax Motors Ltd. (“AutoMax”), a leading parallel |
|
| August 28, 2025 |
SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel Exhibit 99.1 SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel TEL AVIV, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that at adjourned special gener |
|
| August 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2025 (Report No. 4) Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address o |
|
| August 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2025 (Report No. 3) Commission file number: 001- 38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address |
|
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: August (Report No. 2) Commission file number: 001- 38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of p |
|
| August 8, 2025 |
Exhibit 99.1 SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar TEL AVIV, Israel, Aug. 07, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare di |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal exe |
|
| July 31, 2025 |
Exhibit 99.2 SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announces addi |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2025 (Report No. 3) Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of |
|
| July 31, 2025 |
Exhibit 99.1 SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare |
|
| July 22, 2025 |
Exhibit 99.1 SCISPARC LTD. AND ITS SUBSIDIARIES CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2024 U.S. DOLLARS IN THOUSANDS INDEX Page Report of Independent Registered Public Accounting Firm (PCAOB ID 1281) F-2 - F-3 Consolidated Statements of Financial Position F-4 - F-5 Consolidated Statements of Comprehensive Loss F-6 Consolidated Statements of Changes in Equity F-7 Consolidated Stateme |
|
| July 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal execu |
|
| July 22, 2025 |
SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification Exhibit 99.1 SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification Tel Aviv, July 22, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (“SciSparc” or the “Company”) (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, reported the receipt on July 18, 2025 of a writte |
|
| July 22, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 99.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the following Registration Statements: 1. Registration Statements (Form F-3 Nos. 333-275305, 333-269839, 333-266047, 333-248670, and 333-255408) of SciSparc Ltd., and 2. Registration Statements (Form S-8 Nos. 333-278437, 333-225773, and 333-286791) pertaining to the Therapix Biosci |
|
| July 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2025 (Report No. 2) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of |
|
| July 22, 2025 |
As filed with the Securities and Exchange Commission on July 22, 2025 As filed with the Securities and Exchange Commission on July 22, 2025 Registration No. |
|
| July 21, 2025 |
PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT Filed Pursuant to Rule 424(b)(3) Registration No. 333-282351 PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT To the Shareholders of SciSparc Ltd.: You are cordially invited to attend a special meeting of the shareholders of SciSparc Ltd., or SciSparc, an Israeli limited company, which we refer to as “we,” “SciSparc,” or the “Company,” which will be held at 3:00 p.m., local time, on August 25, 2025, at |
|
| July 8, 2025 |
As filed with the Securities and Exchange Commission on July 8, 2025 As filed with the Securities and Exchange Commission on July 8, 2025 Registration No. |
|
| July 8, 2025 |
THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. Exhibit 99.1 SCISPARC LTD. 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916 Israel. VOTE BY INTERNET - www.proxyvote.com Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time, August 24, 2025. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an el |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2025 (Report No. 4) Commission file number: 001- 38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of |
|
| June 26, 2025 |
Exhibit 99.2 COMPENSATION POLICY SCISPARC LTD. Compensation Policy for Executive Officers and Directors (As Adopted on June 26, 2025) A. Overview and Objectives 1. Introduction This document sets forth the Compensation Policy for Executive Officers and Directors (this “Compensation Policy” or “Policy”) of SciSparc Ltd. (“SciSparc” or the “Company”), in accordance with the requirements of the Compa |
|
| June 26, 2025 |
Exhibit 99.1 THE COMPANIES LAW, 1999 A LIMITED LIABILITY COMPANY AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF SCISPARC LTD. As Adopted on June 26, 2025 Preliminary 1. Definitions; Interpretation. (a) In these Articles, the following terms (whether or not capitalized) shall bear the meanings set forth opposite them, respectively, unless the subject or context requires otherwise. “Affiliate” with |
|
| June 25, 2025 |
As filed with the Securities and Exchange Commission on June 25, 2025 As filed with the Securities and Exchange Commission on June 25, 2025 Registration No. |
|
| June 25, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form F-4 (Form Type) SciSparc Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Security Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Sec |
|
| June 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: June (Report No.3) Commission file number: 001- 38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of prin |
|
| June 25, 2025 |
THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. Exhibit 99.1 SCISPARC LTD. 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916 Israel. VOTE BY INTERNET - www.proxyvote.com Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time, August 12, 2025. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an el |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2025 (Report No. 2) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of |
|
| June 24, 2025 |
Exhibit 99.1 SciSparc Announces 1-for-21 Reverse Share Split Following the reverse share split, the Company will have approximately 534,600 outstanding shares, out of which approximately 516,727 will be publicly held Tel Aviv, Israel, June 24, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (“SciSparc” or the “Company”) (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the develo |
|
| June 18, 2025 |
As filed with the Securities and Exchange Commission on June 18, 2025 As filed with the Securities and Exchange Commission on June 18, 2025 Registration No. |
|
| June 10, 2025 |
As filed with the Securities and Exchange Commission on June 9, 2025 As filed with the Securities and Exchange Commission on June 9, 2025 Registration No. |
|
| June 10, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form F-4 (Form Type) SciSparc Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Security Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Sec |
|
| June 10, 2025 |
THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. Exhibit 99.1 SCISPARC LTD. 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916 Israel. VOTE BY INTERNET - www.proxyvote.com Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time, August 5, 2025. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an ele |
|
| June 10, 2025 |
As filed with the Securities and Exchange Commission on June 10, 2025 As filed with the Securities and Exchange Commission on June 10, 2025 Registration No. |
|
| June 9, 2025 |
Exhibit 99.2 AutoMax Motors Ltd. Consolidated Financial Statements for December 31, 2024 AutoMax Motors Ltd. Consolidated Financial Statements for December 31, 2024 Table of Contents Page Auditor’s report to the shareholders F-2 - F-3 Consolidated statements of financial position F-4 - F-5 Consolidated statements of profit and loss F-6 Consolidated statements of comprehensive income F-7 Consolidat |
|
| June 9, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 99.3 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements of SciSparc Ltd (“SciSparc”) on Form F-3 (File No. 333-286099, File No. 333-275305, File No. 333-269839, File No. 333-266047, File No. 333-255408 and File No. and 333-248670) and in the Registration Statements of SciSparc on Form S-8 (File No. 333 |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2025 Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal execu |
|
| June 9, 2025 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION As previously disclosed, on April 10, 2024, SciSparc Ltd., or the Parent Company or SciSparc entered into an Agreement and Plan of Merger with AutoMax Motors Ltd., an Israeli company traded on the Tel Aviv Stock Exchange and the leading parallel importer and distributor of vehicles in Israel, or AutoMax, and SciSparc Merger |
|
| May 27, 2025 |
SciSparc Announces Publication of Japanese Patent Application Exhibit 99.1 SciSparc Announces Publication of Japanese Patent Application TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today the publication of a Japanese divisional pat |
|
| May 27, 2025 |
As filed with the Securities and Exchange Commission on May 27, 2025 As filed with the Securities and Exchange Commission on May 27, 2025 Registration No. |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2025 (Report No. 3) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of p |
|
| May 27, 2025 |
THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. Exhibit 99.1 SCISPARC LTD. 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916 Israel. VOTE BY INTERNET - www.proxyvote.com Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time, , 2025. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic |
|
| May 21, 2025 |
THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. Exhibit 99.2 SCISPARC LTD. 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916 Israel. VOTE BY INTERNET - www.proxyvote.com Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time, June 24, 2025. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an elec |
|
| May 21, 2025 |
Notice of Annual General Meeting of Shareholders To be Held on June 25, 2025 Exhibit 99.1 May 21, 2025 Dear SciSparc Ltd. Shareholders: We cordially invite you to attend the Annual General Meeting of Shareholders of SciSparc Ltd. (the “Meeting”), to be held on Wednesday, June 25, 2025 at 3:00 p.m. (Israel time), at the Company’s offices, at 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel. At the Meeting, shareholders will be asked to consider and vote on the ma |
|
| May 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of: May 2025 (Report No. 2) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916, Israel (Address of |
|
| May 14, 2025 |
AMENDMENT No. 3 TO LOAN AGREEMENT Exhibit 10.5 AMENDMENT No. 3 TO LOAN AGREEMENT This Amendment (the “Amendment”) to that certain Loan Agreement dated January 14, 2024, as amended by Amendment No. 1 dated June 9, 2024 and Amendment No. 2 dated September 5, 2024 (“Amendment No. 2”) (together, the “Loan Agreement”), by and between SciSparc Ltd., an Israeli limited company (the “Lender”), and AutoMax Motors Ltd., an Israeli limited c |
|
| May 14, 2025 |
As filed with the Securities and Exchange Commission on May 14, 2025 As filed with the Securities and Exchange Commission on May 14, 2025 Registration No. |
|
| May 13, 2025 |
EX-99.1 2 ea024170802ex99-1scisparc.htm PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC-CLEARMIND COLLABORATION LEADS TO PUBLICATION OF EUROPEAN PATENT FOR PSYCHEDELIC-BASED COMBINATION THERAPY FOR COCAINE ADDICTION." Exhibit 99.1 SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction AVIV, Israel, May 12, 202 |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2025 Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal execut |
|
| April 29, 2025 |
As filed with the Securities and Exchange Commission on April 28, 2025 As filed with the Securities and Exchange Commission on April 28, 2025 Registration No. |
|
| April 28, 2025 |
Exhibit 107.1 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) SCISPARC LTD. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee SciSparc Ltd. 2023 Share Incen |
|
| April 28, 2025 |
As filed with the Securities and Exchange Commission on April 28, 2025 As filed with the Securities and Exchange Commission on April 28, 2025 Registration No. |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2025 (Report No. 2) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of |
|
| April 25, 2025 |
Exhibit 99.1 SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders TEL AVIV, Israel, April 25, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the centr |
|
| April 24, 2025 |
addendum no. 3 to AGREEMENT AND PLAN OF MERGER Exhibit 4.25 addendum no. 3 to AGREEMENT AND PLAN OF MERGER This addendum, dated March 27, 2025 (the “Effective Date”) constitutes addendum no. 3 (the “Addendum”) to that certain Agreement and Plan Of Merger dated April 10, 2024, as amended by Addendum No. 1 dated August 14, 2024, and Addendum No. 2 dated November 26, 2024 (hereinafter together, the “Agreement”), by and between, SciSparc Ltd., an |
|
| April 24, 2025 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) OR 15d-14(a) Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) OR 15d-14(a) I, Oz Adler, certify that: 1. I have reviewed this annual report on Form 20–F of SciSparc Ltd. (the “Company”); 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances unde |
|
| April 24, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 Kost Forer Gabbay & Kasierer 144 Menachem Begin Road, Building A Tel-Aviv 6492102, Israel Tel: +972-3-6232525 Fax: +972-3-5622555 ey.com CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statements (Form F-3 Nos. 333-269839, 333-266047, 333-248670, and 333-255408) of SciSparc |
|
| April 24, 2025 |
Exhibit 2.1 DESCRIPTION OF SHARE CAPITAL The following description of SciSparc Ltd.’s (the “Company”) share capital and provisions of the amended and restated articles of association (the “Articles”) are summaries and do not purport to be complete. Registration number and purposes of the Company Our registration number with the Israeli Registrar of Companies is 51-358165-2. Our purpose as set fort |
|
| April 24, 2025 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2024 (the “Report”) by SpiSparc Ltd. (the “Company”), the undersigned, as the Chief Executive Officer and Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report ful |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. |
|
| April 24, 2025 |
Exhibit 11.1 SCISPARC LTD. INSIDER TRADING POLICY AND GUIDELINES WITH RESPECT TO CERTAIN TRANSACTIONS IN COMPANY SECURITIES Date: April 23, 2025 This Insider Trading Policy (the “Policy”) provides guidelines to directors, officers, employees and other related individuals of SciSparc Ltd., an Israeli company (the “Company”), with respect to transactions in the Company’s securities. The Company has |
|
| April 1, 2025 |
Filed by SciSparc Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: AutoMax Motors Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2025 (Report No. 1) Commission file number: 001-38041 SCISPAR |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2025 (Report No. 1) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2025 (Report No. 2) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of |
|
| March 25, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form F-3 (Form Type) SciSparc Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, no par value 457( |
|
| March 25, 2025 |
As filed with the Securities and Exchange Commission on March 25, 2025 As filed with the Securities and Exchange Commission on March 25, 2025 Registration No. |
|
| March 11, 2025 |
As filed with the Securities and Exchange Commission on March 10, 2025 As filed with the Securities and Exchange Commission on March 10, 2025 Registration No. |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2025 (Report No. 2) Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of |
|
| March 11, 2025 |
THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. Exhibit 99.1 SCISPARC LTD. 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916 Israel. VOTE BY INTERNET - www.proxyvote.com Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time, , 2025. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic |
|
| March 11, 2025 |
Exhibit 10.8 Loan Agreement This Loan Agreement (the “Agreement”) is made on February 24, 2025 (the “Effective Date”) by and between, SciSparc Ltd., an Israeli limited company (the “Lender”) and AutoMax Motors Ltd., an Israeli limited company (the “Borrower”). WHEREAS, the Lender is willing to extend a loan to the Borrower, under the terms and conditions set forth herein. NOW, THEREFORE, the parti |
|
| March 11, 2025 |
Exhibit 99.1 SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea TEL AVIV, Israel, March 10, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central ner |
|
| March 3, 2025 |
Exhibit 99.1 SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers SciSparc will sell its MitoCareX’s shares for $700,000 and exchange its remaining shares for common stock in N2OFF TEL AVIV, Israel, March 03, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutica |
|
| March 3, 2025 |
SECURITIES PURCHASE AND EXCHANGE AGREEMENT Exhibit 10.1 Execution Version SECURITIES PURCHASE AND EXCHANGE AGREEMENT This SECURITIES PURCHASE AND EXCHANGE AGREEMENT (the “Agreement”) is entered into as of February 25, 2025 by and among N2OFF, Inc., a Nevada corporation, with an office address of HaPardes 134 (Meshek Sander), Neve Yarak, Israel (“N2OFF” or the “Purchaser”), MitoCareX Bio Ltd., a private company incorporated under the laws o |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal exec |
|
| February 27, 2025 |
ORDINARY SHARES PURCHASE WARRANT SCISPARC LTD. Exhibit 4.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T |
|
| February 27, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of February 24, 2025, is between SCISPARC LTD., a company incorporated under the laws of the State of Israel, with principal executive offices located at 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (the “Company”), and each of the investors listed on the Schedule of Buyers att |
|
| February 27, 2025 |
Exhibit 10.3 GLOBAL GUARANTY AGREEMENT This Guaranty is made as of February 25, 2025 by BRAIN BRIGHT LTD., (“Brain Bright”) and EVERO HEALTH LTD., (“Evero Health” and collectively with Brain Bright, the “Guarantors”) in favor of YA II PN, LTD. (the “Creditor”), with respect to all obligations of SCISPARC LTD., a company incorporated under the laws of the State of Israel (the “Debtor”) owed to the |
|
| February 27, 2025 |
Exhibit 99.1 SciSparc Extends $2 Million Loan to Support AutoMax’s Growth Following AutoMax’s Entry into Direct Import of JAC Electric Vehicles TEL AVIV, Israel, Feb. 27, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, anno |
|
| February 27, 2025 |
Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of February 25, 2025, is made by and between YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”), and SCISPARC LTD., a company incorporated under the laws of the State of Israel (the “Company”). The Investor and the Company may be referred to herein individually as a “Par |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2025 (Report No. 3) Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address |
|
| February 27, 2025 |
Filed by SciSparc Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: AutoMax Motors Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2025 (Report No. 3) Commission File Number: 001-38041 SCIS |
|
| February 27, 2025 |
SCISPARC LTD. Convertible Debenture Exhibit 4.1 NEITHER THIS DEBENTURE NOR THE SECURITIES INTO WHICH THIS DEBENTURE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXC |
|
| February 27, 2025 |
Exhibit 10.5 Loan Agreement This Loan Agreement (the “Agreement”) is made on February 24, 2025 (the “Effective Date”) by and between, SciSparc Ltd., an Israeli limited company (the “Lender”) and AutoMax Motors Ltd., an Israeli limited company (the “Borrower”). WHEREAS, the Lender is willing to extend a loan to the Borrower, under the terms and conditions set forth herein. NOW, THEREFORE, the parti |
|
| February 27, 2025 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of February 25, 2025, is between SCISPARC LTD., a company incorporated under the laws of the State of Israel, with principal executive offices located at 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (the “Company”), and each of the investors listed on the Schedule of Buyers att |
|
| February 18, 2025 |
Exhibit 99.1 SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2025 (Report No. 2) Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address |
|
| February 13, 2025 |
As filed with the Securities and Exchange Commission on February 13, 2025 As filed with the Securities and Exchange Commission on February 13, 2025 Registration No. |
|
| February 13, 2025 |
Exhibit 10.6 Certain identified information contained in this document, marked by brackets, was omitted because it is both (i) not material and (ii) is the type that the Company treats as private or confidential. “[***]” indicates where the information has been omitted from this exhibit. DISTRIBUTION AGREEMENT By and Between ANHUI JIANGHUAI AUTOMOBILE GROUP CORP., LTD. And AUTOMAX LEASING COMPANY |
|
| February 13, 2025 |
Exhibit 10.7 Certain identified information contained in this document, marked by brackets, was omitted because it is both (i) not material and (ii) is the type that the Company treats as private or confidential. “[***]” indicates where the information has been omitted from this exhibit. TRANSLATED FROM HEBREW FOR CONVENIENCE PURPOSES ONLY Founders’ Agreement That was made and signed in Tel Aviv o |
|
| February 4, 2025 |
Exhibit 99.1 SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico TEL AVIV, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, annou |
|
| February 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal e |
|
| January 21, 2025 |
As filed with the Securities and Exchange Commission on January 21, 2025 As filed with the Securities and Exchange Commission on January 21, 2025 Registration No. |
|
| January 15, 2025 |
No Immediate Effect on Nasdaq Listing or Trading of the Company’s Ordinary Shares Exhibit 99.1 SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement No Immediate Effect on Nasdaq Listing or Trading of the Company’s Ordinary Shares TEL AVIV, Israel, Jan. 15, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat dis |
|
| January 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 (Report No. 2) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address |
|
| January 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal ex |
|
| January 7, 2025 |
Exhibit 99.1 SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment TEL AVIV, Israel, Jan. 06, 2025 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central ner |
|
| December 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 (Report No. 3) Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address |
|
| December 31, 2024 |
As filed with the Securities and Exchange Commission on December 31, 2024 As filed with the Securities and Exchange Commission on December 31, 2024 Registration No. |
|
| December 31, 2024 |
addendum no. 2 to AGREEMENT AND PLAN OF MERGER Exhibit 2.4 addendum no. 2 to AGREEMENT AND PLAN OF MERGER This addendum, dated November 26, 2024 (the “Effective Date”) constitutes addendum no. 2 (the “Addendum”) to that certain Agreement and Plan Of Merger dated April 10, 2024, as amended by Addendum No. 1 dated August 14, 2024 (hereinafter together, the “Agreement”), by and between, SciSparc Ltd., an Israeli limited company (the “Parent”), Sc |
|
| December 31, 2024 |
Exhibit 10.7 Certain confidential information contained in this document, marked by brackets, was omitted because it is both (i) not material and (ii) would likely cause competitive harm to the Company if publicly disclosed. “[***]” indicates where the information has been omitted from this exhibit. TRANSLATED FROM HEBREW FOR CONVENIENCE PURPOSES ONLY Founders’ Agreement That was made and signed i |
|
| December 31, 2024 |
Exhibit 10.6 Certain confidential information contained in this document, marked by brackets, was omitted because it is both (i) not material and (ii) would likely cause competitive harm to the Company if publicly disclosed. “[***]” indicates where the information has been omitted from this exhibit. DISTRIBUTION AGREEMENT By and Between ANHUI JIANGHUAI AUTOMOBILE GROUP CORP., LTD. And AUTOMAX LEAS |
|
| December 31, 2024 |
Exhibit 99.1 SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder TEL AVIV, Israel, Dec. 31, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, |
|
| December 26, 2024 |
Exhibit 99.1 SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation TEL AVIV, Israel, Dec. 27, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), announced that AutoMax Motors Ltd., (“AutoMax”), a leading automotive importer and distributor in Israel with which the Company has entered into an agreemen |
|
| December 26, 2024 |
6-K 1 ea0226065-6kscisparc.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 (Report No. 2) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 R |
|
| December 26, 2024 |
Filed by SciSparc Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: AutoMax Motors Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 (Report No. 2) Commission file number: 001-38041 SCIS |
|
| December 17, 2024 |
Exhibit 99.1 SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company According to the LOI, SciSparc’s pharmaceuticals assets are valued at approximately US$11.6 million TEL AVIV, Israel, Dec. 16, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical compa |
|
| December 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal e |
|
| November 29, 2024 |
Filed by SciSparc Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: AutoMax Motors Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 (Report No. 3) Commission file number: 001-38041 SCIS |
|
| November 29, 2024 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION As previously disclosed, on April 10, 2024, SciSparc Ltd., or the Parent Company or SciSparc entered into an Agreement and Plan of Merger with AutoMax Motors Ltd., an Israeli company traded on the TASE and the leading parallel importer and distributor of vehicles in Israel, or AutoMax, and SciSparc Merger Sub Ltd., an Israel |
|
| November 29, 2024 |
Exhibit 99.2 AutoMax Motors Ltd. Summary of Interim Consolidated Financial Information June 30, 2024 (Unaudited) AutoMax Motors Ltd. Consolidated Financial Statements June 30, 2024 Table of Contents Page Auditor’s review report for shareholders Summary of statements on the consolidated interim financial condition F-2 - F-3 Summary of consolidated interim profit and loss reports F-4 Summary of cons |
|
| November 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 (Report No. 3) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 (Report No. 2) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address |
|
| November 27, 2024 |
Filed by SciSparc Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: AutoMax Motors Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 (Report No. 2) Commission file number: 001-38041 SCIS |
|
| November 4, 2024 |
SCISPARC LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 Exhibit 99.1 SCISPARC LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 UNAUDITED INDEX Page Consolidated Statements of Financial Position 2-3 Consolidated Statements of Profit or Loss and Other Comprehensive Loss 4 Consolidated Statements of Changes in Equity (Deficit) 5-7 Consolidated Statements of Cash Flows 8-10 Notes to Interim Consolidated Financial Statements 11-23 SCISPARC |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal e |
|
| November 4, 2024 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations provides information that we believe to be relevant to an assessment and understanding of our results of operations and financial condition for the periods described. This discussion should be read in conjuncti |
|
| October 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2024 (Report No. 2) Commission file number: 001- 38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address |
|
| October 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2024 (Report No. 1) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address |
|
| September 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of: September 2024 (Report No. 6) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916, Israel (Addre |
|
| September 27, 2024 |
Supplemental Proxy Statement Annual General Meeting of Shareholders to be held on October 22, 2024 Exhibit 99.1 September 27, 2024 Supplemental Proxy Statement Annual General Meeting of Shareholders to be held on October 22, 2024 This supplemental proxy statement (the “Supplemental Proxy Statement”) is being furnished in connection with the solicitation of proxies on behalf of the board of directors (the “Board”), of SciSparc Ltd. (“SciSparc” or the “Company”) to be voted at the Annual General |
|
| September 27, 2024 |
THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. Exhibit 99.2 SCISPARC LTD. 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916 Israel. VOTE BY INTERNET - www.proxyvote.com Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time, Monday, October 21, 2024. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to cre |
|
| September 26, 2024 |
FORM OF indemnification agreement Exhibit 10.5 FORM OF indemnification agreement THIS INDEMNIFICATION AGREEMENT (the “Agreement”), dated as of , 2024, is entered into by and between SciSparc Ltd., an Israeli company whose address is 20 Raul Wallenberg St., Tower A, 2nd Floor, Tel Aviv 6971916, Israel (the “Company”), and the undersigned Director or Officer of the Company whose name appears on the signature page hereto officer (the |
|
| September 26, 2024 |
CONSENT TO BE NAMED AS DIRECTOR Exhibit 99.4 CONSENT TO BE NAMED AS DIRECTOR In connection with the Registration Statement on Form F-4 (including any and all amendments, including post-effective amendments, or supplements thereto, the “Registration Statement”) of SciSparc Ltd. (the “Company”), the undersigned hereby consents to being named and described in the Registration Statement filed with the U.S. Securities and Exchange Co |
|
| September 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2024 (Report No. 5) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Addres |
|
| September 26, 2024 |
SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX Exhibit 99.1 SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX The intended selling valuation represents an increase of 47% from the valuation at the time of SciSparc’s initial investment in MitoCareX Bio TEL AVIV, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on |
|
| September 26, 2024 |
As filed with the Securities and Exchange Commission on September 26, 2024 As filed with the Securities and Exchange Commission on September 26, 2024 Registration No. |
|
| September 26, 2024 |
PREFUNDED ORDINARY SHARE PURCHASE WARRANT SCISPARC LTD. Exhibit 4.1 PREFUNDED ORDINARY SHARE PURCHASE WARRANT SCISPARC LTD. Warrant Shares: Date of Issuance: , 2024(“Issuance Date”) This PREFUNDED ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received (in connection with the issuance of the Merger Consideration (as defined in the Merger Agreement (as defined below), [HOLDER] (including any permitted and registered assigns, t |
|
| September 26, 2024 |
Exhibit 10.3 AMENDMENT TO LOAN AGREEMENT This Amendment (the “Amendment”) to that certain Loan Agreement (“Loan Agreement”) dated January 14, 2024 (the “Effective Date”), by and between SciSparc Ltd., an Israeli limited Company (the “Lender”), and AutoMax Motors Ltd., an Israeli limited company (the “Borrower”), is entered into effect as of June 9, 2024 (the “Amendment Effective Date”). Unless oth |
|
| September 26, 2024 |
Exhibit 10.2 Loan Agreement This Loan Agreement (the “Agreement”) is made on January 14, 2024 (the “Effective Date”) by and between, SciSparc Ltd., an Israeli limited company (the “Lender”) and AutoMax Motors Ltd., an Israeli limited company (the “Borrower”). WHEREAS, the Borrower and the Lender intend to enter into a merger agreement, upon consummation of which the Borrower will become a wholly o |
|
| September 26, 2024 |
AMENDMENT No. 2 TO LOAN AGREEMENT Exhibit 10.4 AMENDMENT No. 2 TO LOAN AGREEMENT This Amendment (the “Amendment”) to that certain Loan Agreement dated January 14, 2024, as amended by Amendment dated June 9, 2024 (together, the “Loan Agreement”), by and between SciSparc Ltd., an Israeli limited Company (the “Lender”), and AutoMax Motors Ltd., an Israeli limited company (the “Borrower”), is entered into effect as of September 5, 202 |
|
| September 26, 2024 |
WRITTEN CONSENT OF E.D.B. CONSULTING AND INVESTMENTS LTD July 16 2024 Exhibit 99.2 WRITTEN CONSENT OF E.D.B. CONSULTING AND INVESTMENTS LTD July 16 2024 The Board of Directors SciSparc Ltd. 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel To the Board of Directors of SciSparc Ltd. We refer to the valuation report of our firm, dated January 9, 2024 (the “Valuation Report”), included in the proxy statement/prospectus on Form F-4 (the “Registration Statement |
|
| September 26, 2024 |
addendum no. 1 to AGREEMENT AND PLAN OF MERGER Exhibit 2.3 addendum no. 1 to AGREEMENT AND PLAN OF MERGER This addendum, dated August 14, 2024 (the “Effective Date”) constitutes addendum no. 1 (the “Addendum”) to that certain Agreement and Plan Of Merger dated April 10, 2024 (hereinafter together, the “Agreement”), by and between, SciSparc Ltd., an Israeli limited company (the “Parent”), SciSparc Merger Sub Ltd., an Israeli limited company and |
|
| September 26, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form F-4 (Form Type) SciSparc Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Security Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Sec |
|
| September 26, 2024 |
CONSENT TO BE NAMED AS DIRECTOR Exhibit 99.3 CONSENT TO BE NAMED AS DIRECTOR In connection with the Registration Statement on Form F-4 (including any and all amendments, including post-effective amendments, or supplements thereto, the “Registration Statement”) of SciSparc Ltd. (the “Company”), the undersigned hereby consents to being named and described in the Registration Statement filed with the U.S. Securities and Exchange Co |
|
| September 23, 2024 |
Exhibit 99.1 SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment FDA confirms that SciSparc’s study may proceed following the application submission a month ago TEL AVIV, Israel, Sept. 23, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of th |
|
| September 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2024 (Report No. 4) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Addres |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2024 (Report No. 3) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Addres |
|
| September 16, 2024 |
Exhibit 99.1 SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy This innovative drug combination treatment focuses on boosting safety and efficacy in mental health and addiction care TEL AVIV, Israel, Sept. 16, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a special |
|
| September 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2024 (Report No. 2) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Addres |
|
| September 11, 2024 |
Filed by SciSparc Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: AutoMax Motors Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2024 (Report No. 2) Commission file number: 001-38041 SCI |
|
| September 11, 2024 |
Exhibit 99.1 SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax’s Direct Import Agreement with Major Chinese Vehicle Manufacturer To date, SciSparc has advanced $4.25 million to Automax under the Bridge Loan agreement and amendments thereto TEL AVIV, Israel, Sept. 11, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmace |
|
| September 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2024 Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal |
|
| September 6, 2024 |
Exhibit 99.1 SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacy in Mental Health and Addiction Treatments TEL AVIV, Israel, Sept. 06, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-s |
|
| September 3, 2024 |
SciSparc Ltd. 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916, Israel SciSparc Ltd. 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916, Israel September 3, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: SciSparc Ltd. (CIK 0001611746) Registration Statement No. 333-281821 on Form F-1 (the “Registration Statement”) Ladies and Gentlemen: SciSparc Ltd. (the “Registrant”) hereby requests acc |
|
| August 29, 2024 |
Exhibit 99.1 SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination TEL AVIV, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, a |
|
| August 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2024 (Report No. 8) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address o |
|
| August 28, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM F-1 (Form Type) SCISPARC LTD. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (2)(3) Maximum Aggregate Offering Price Fee Rate Amount of Registration F |
|
| August 28, 2024 |
addendum no. 1 to AGREEMENT AND PLAN OF MERGER Exhibit 2.2 addendum no. 1 to AGREEMENT AND PLAN OF MERGER This addendum, dated August 14, 2024 (the “Effective Date”) constitutes addendum no. 1 (the “Addendum”) to that certain Agreement and Plan Of Merger dated April 10, 2024 (hereinafter together, the “Agreement”), by and between, SciSparc Ltd., an Israeli limited company (the “Parent”), SciSparc Merger Sub Ltd., an Israeli limited company and |
|
| August 28, 2024 |
As filed with the Securities and Exchange Commission on August 28, 2024 As filed with the Securities and Exchange Commission on August 28, 2024 Registration No. |
|
| August 26, 2024 |
Exhibit 99.1 SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome SciSparc to conduct the trial at the Yale Child Study Center at the Yale School of Medicine in the USA, Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel TEL AVIV, Israel, Aug. 23, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (" |
|
| August 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2024 (Report No. 7) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address o |
|
| August 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of: August 2024 (Report No. 6) Commission file number: 001- 38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916, Israel (Address |
|
| August 22, 2024 |
Notice of Annual General Meeting of Shareholders To be Held on October 1, 2024 Exhibit 99.1 August 22, 2024 Dear SciSparc Ltd. Shareholders: We cordially invite you to attend the Annual General Meeting of Shareholders of SciSparc Ltd. (the “Meeting”), to be held on Tuesday, October 1, 2024 at 3:00 p.m. (Israel time), at the Company’s offices, at 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916 Israel. At the Meeting, shareholders will be asked to consider and vote on the |
|
| August 22, 2024 |
THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. Exhibit 99.2 SCISPARC LTD. 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916 Israel. VOTE BY INTERNET - www.proxyvote.com Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time, Monday, September 30, 2024. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to c |
|
| August 20, 2024 |
Exhibit 99.1 SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment The clinical trial for SCI-210 is conducted in Israel, after which the Company aims to move forward with the commercialization process of SCI-210, first in the Israeli market TEL AVIV, Israel, Aug. 19, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “Sc |
|
| August 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2024 (Report No. 5) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address o |
|
| August 19, 2024 |
Exhibit 99.1 SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million SciSparc will receive consideration in shares, and in addition may receive cash payments and fees if certain development milestones are met TEL AVIV, Israel, Aug. 16, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceuti |
|
| August 19, 2024 |
Exclusive Patent License Agreement Exhibit 10.1 Exclusive Patent License Agreement This Exclusive Patent License Agreement (the “Agreement”), effective as of the date set forth above the signatures of the parties below (the “Effective Date”), is between SciSparc Ltd., an Israeli company, with a principal office at 20 Raul Walenberg St., Tel Aviv, Israel (“Licensor”) and Polyrizon Ltd., an Israeli corporation, with a principal place |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2024 (Report No. 4) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address o |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2024 (Report No. 3) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address o |
|
| August 14, 2024 |
Exhibit 99.1 SciSparc Updates Regarding the Status of the AutoMax Merger SciSparc provides investors with an update regarding the status of the merger agreement with AutoMax, including the court’s approval of AutoMax’s petition to convene special class meetings of its shareholders to approve the Merger with the Company TEL AVIV, Israel, Aug. 14, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) |
|
| August 14, 2024 |
Filed by SciSparc Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: AutoMax Motors Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2024 (Report No. 3) Commission file number: 001-38041 SCISPA |
|
| August 13, 2024 |
Filed by SciSparc Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: AutoMax Motors Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2024 (Report No. 2) Commission file number: 001-38041 SCISPA |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2024 (Report No. 2) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address o |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2024 Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal exe |
|
| August 6, 2024 |
Exhibit 99.1 SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug SciSparc has been collaborating with Clearmind Medicine to create effective treatments for obesity and metabolic syndrome by combining SciSparc’s Palmitoylethanolamide (PEA) with Clearmind’s MEAI TEL AVIV, Israel, August 6, 2024 (GLOBE |
|
| July 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2024 (Report No. 5) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of |
|
| July 23, 2024 |
Exhibit 99.1 SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer The discovery was demonstrated by utilizing genetic manipulations and 3D spheroid systems, mimicking the main features of human solid tumors TEL AVIV, Israel, July 22, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pha |
|
| July 17, 2024 |
Exhibit 99.1 SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million SciSparc will receive additional payments and execution fees if certain milestones are met TEL AVIV, Israel, July 17, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on t |
|
| July 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2024 (Report No. 4) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of |
|
| July 16, 2024 |
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification Exhibit 99.1 SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification TEL AVIV, Israel, July 16, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system (the “Company” or “SciSparc”), today announced it has received a written no |
|
| July 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2024 (Report No. 3) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of |
|
| July 16, 2024 |
SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss Exhibit 99.1 SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss TEL AVIV, Israel, July 16, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced that an additional p |
|
| July 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2024 (Report No. 2) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of |
|
| July 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2024 Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal execu |
|
| July 8, 2024 |
Exhibit 99.1 SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company According to the agreement, SciSparc’s pharmaceuticals assets are valued at approximately $11.6 million TEL AVIV, Israel, July 08, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutica |
|
| June 17, 2024 |
Exhibit 10.25 AMENDMENT TO LOAN AGREEMENT This Amendment (the “Amendment”) to that certain Loan Agreement (“Loan Agreement”) dated January 14, 2024 (the “Effective Date”), by and between SciSparc Ltd., an Israeli limited Company (the “Lender”), and AutoMax Motors Ltd., an Israeli limited company (the “Borrower”), is entered into effect as of June 9, 2024 (the “Amendment Effective Date”). Unless ot |
|
| June 17, 2024 |
Exhibit 10.24 Loan Agreement This Loan Agreement (the “Agreement”) is made on January 14, 2024 (the “Effective Date”) by and between, SciSparc Ltd., an Israeli limited company (the “Lender”) and AutoMax Motors Ltd., an Israeli limited company (the “Borrower”). WHEREAS, the Borrower and the Lender intend to enter into a merger agreement, upon consummation of which the Borrower will become a wholly |
|
| June 17, 2024 |
SciSparc Ltd. 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916, Israel SciSparc Ltd. 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916, Israel June 17, 2024 Via EDGAR Jimmy McNamara Alan Campbell Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Re: SciSparc Ltd. (the “Company”) Post-Effective Amendment No. 1 to Registration Statement on Form F-1 (File No. 333-277394) Filed on May 2, 202 |
|
| June 17, 2024 |
As filed with the Securities and Exchange Commission on June 17, 2024 As filed with the Securities and Exchange Commission on June 17, 2024 Registration No. |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2024 (Report No. 2) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2024 Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal execu |
|
| June 3, 2024 |
SciSparc Secures Strategic Advantage with Grant of European Patent Exhibit 99.1 SciSparc Secures Strategic Advantage with Grant of European Patent TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that the European Patent Office granted |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F/A ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. |
|
| May 2, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 99.3 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in registration statements on Form F-3 (File No. 333-275305, File No. 333-269839, File No. 333-266047, File No. 333-233417, File No. 333-248670 and File No. 333-255408) and on Form S-8 (File Nos. 333-225773 and 333-278437) of SciSparc Ltd. of our report dated March 31, 2024, with resp |
|
| May 2, 2024 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION As previously disclosed, on April 10, 2024, SciSparc Ltd. (“SciSparc”) entered into an Agreement and Plan of Merger with AutoMax Motors Ltd., an Israeli company traded on the Tel Aviv Stock Exchange (“TASE”) and the leading parallel importer and distributor of vehicles in Israel (“AutoMax”), and SciSparc Merger Sub Ltd., an |
|
| May 2, 2024 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F/A for the period ended December 31, 2023 (the “Report”) by SpiSparc Ltd. (the “Company”), the undersigned, as the Chief Executive Officer and Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report f |
|
| May 2, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statements filed by SciSparc Ltd. (the “Company”) on Form S-8 (File No. 333-225773 and 333-278437) and on Form F-3 (File Nos. 333-269839, 333-266047, 333-233417, 333-248670, 333-255408 and 333-275305) of our report dated April 1, 2024, with respect to the consolida |
|
| May 2, 2024 |
As filed with the Securities and Exchange Commission on May 2, 2024 As filed with the Securities and Exchange Commission on May 2, 2024 Registration No. |
|
| May 2, 2024 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) OR 15d-14(a) Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) OR 15d-14(a) I, Oz Adler, certify that: 1. I have reviewed this annual report on Form 20–F/A of SciSparc Ltd. (the “Company”); 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances un |
|
| May 2, 2024 |
Exhibit 99.1 Automax Motors Ltd. Consolidated Financial Statements as for December 31, 2023 Automax Motors Ltd. Consolidated Financial Statements as for December 31, 2023 Table of Contents: Page Auditor’s report to the shareholders F-2 - F-3 Consolidated statements of financial position F-4 - F-5 Consolidated statements of profit and loss F-6 Consolidated statements of comprehensive income F-7 Con |
|
| May 2, 2024 |
Filed by SciSparc Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: AutoMax Motors Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2024 Commission file number: 001-38041 SCISPARC LTD. (Translati |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2024 Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal execut |
|
| April 12, 2024 |
Filed by SciSparc Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: AutoMax Motors Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2024 Commission file number: 001-38041 SCISPARC LTD. (Transla |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2024 Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal exec |
|
| April 11, 2024 |
Exhibit 99.3 SciSparc to Acquire AutoMax TEL AVIV, Israel, April 11, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that it signed a merger agreement (the “Agreement”) with AutoMax Motors Ltd. |
|
| April 11, 2024 |
Exhibit 99.1 Execution Copy AGREEMENT AND PLAN OF MERGER among SCISPARC LTD., an Israeli limited company; SCISPARC MERGER SUB LTD., an Israeli limited company; and AUTOMAX MOTORS LTD., an Israeli limited company Dated as of April 10, 2024 TABLE OF CONTENTS 1. DESCRIPTION OF TRANSACTION 2 1.1 The Merger 2 1.2 Effects of the Merger 2 1.3 Closing; Effective Time 2 1.4 Articles of Association; Directo |
|
| April 11, 2024 |
Exhibit 99.2 Execution Copy SHAREHOLDER SUPPORT AGREEMENT This Shareholder Support Agreement, dated as of April 10, 2024 (this “Agreement”), is entered into by and among SciSparc Ltd., an Israeli limited company (the “Parent”) and each of the shareholders of AutoMax Motors Ltd. (the “Company”) listed on Schedule I hereto (the “Shareholders”). W I T N E S S E T H: WHEREAS, Parent, SciSparc Merger S |
|
| April 1, 2024 |
SCISPARC LTD. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Exhibit 97.1 SCISPARC LTD. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION SciSparc Ltd. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subject to Policy This Policy sha |
|
| April 1, 2024 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) OR 15d-14(a) Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) OR 15d-14(a) I, Oz Adler, certify that: 1. I have reviewed this annual report on Form 20–F of SciSparc Ltd. (the “Company”); 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances unde |
|
| April 1, 2024 |
Exhibit 107.1 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) SCISPARC LTD. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee SciSparc Ltd. 2023 Share Incent |
|
| April 1, 2024 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2023 (the “Report”) by SpiSparc Ltd. (the “Company”), the undersigned, as the Chief Executive Officer and Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report ful |
|
| April 1, 2024 |
Exhibit 2.1 DESCRIPTION OF SHARE CAPITAL The following description of SciSparc Ltd.’s (the “Company”) share capital and provisions of the amended and restated articles of association (the “Articles”) are summaries and do not purport to be complete. Registration number and purposes of the Company Our registration number with the Israeli Registrar of Companies is 51-358165-2. Our purpose as set fort |
|
| April 1, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statement on Form S-8 (File No. 333-225773) pertaining to SciSparc Ltd.’s (the “Company”) Israeli Share Option Plan (2005) and Israeli Share Option Plan (2015) and in the Registration Statements on Form F-3 (File Nos. 333-269839, 333-266047, 333-233417, 333-248670, |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. |
|
| April 1, 2024 |
As filed with the Securities and Exchange Commission on April 1, 2024 As filed with the Securities and Exchange Commission on April 1, 2024 Registration No. |
|
| March 27, 2024 |
Exhibit 99.1 SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression TEL AVIV, Israel, March 27, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous syste |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2024 (Report No. 4) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2024 (Report No. 3) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of |
|
| March 15, 2024 |
Exhibit 99.1 SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial First patient has been dosed in the randomized, controlled, double blind clinical trial for Autism Spectrum Disorder in pediatric patients TEL AVIV, Israel, March 14, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceuti |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2024 (Report No. 2) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of |
|
| March 8, 2024 |
SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe Exhibit 99.2 SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe The Company’s most recent patent further solidifies its position, complementing existing grants in the U.S., Japan, Australia and other key jurisdictions TEL AVIV, Israel, March 07, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical com |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2024 Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal exec |
|
| March 8, 2024 |
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology Exhibit 99.1 SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology TEL AVIV, Israel, March 06, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today its had been rec |
|
| March 8, 2024 |
Exhibit 99.3 SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder TEL AVIV, Israel, March 08, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that the |
|
| March 6, 2024 |
EX-99.1 2 tm248112d1ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the equity securities of SciSparc Ltd. is, and any amendment thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) promulgated under |
|
| March 6, 2024 |
SPRC / SciSparc Ltd. / YA II PN, Ltd. - FORM 13-G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 SciSparc Ltd. (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) M82618113 (CUSIP Number) February 27, 2024 (Date of Event, which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| March 5, 2024 |
SciSparc Ltd. 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916, Israel SciSparc Ltd. 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916, Israel March 5, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: SciSparc Ltd. (CIK 0001611746) Registration Statement No. 333-277394 on Form F-1 (the “Registration Statement”) Ladies and Gentlemen: SciSparc Ltd. (the “Registrant”) hereby requests acceler |
|
| February 29, 2024 |
Exhibit 99.1 SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing The SCI- 210 treatment is now available at clinical site for autism spectrum disorder clinical trial in pediatric patients, in accordance with enrollment initiation TEL AVIV, Israel, Feb. 29, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2024 (Report No. 4) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address |
|
| February 27, 2024 |
Exhibit 21.1 List of Subsidiaries Name of Subsidiary Jurisdiction Ownership Interest Brain Bright Ltd. Israel 100% Evero Health Ltd. Israel 100% Scisparc Nutraceuticals Inc. Delaware 50.86% |
|
| February 27, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM F-1 ………….. (Form Type) SCISPARC LTD. ……………………………………………………..… (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(2)(3) Maximum Aggregate Offering Price Fee |
|
| February 27, 2024 |
Exhibit 99.1 SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds TEL AVIV, Israel, Feb. 27, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous syste |
|
| February 27, 2024 |
As filed with the Securities and Exchange Commission on February 27, 2024 As filed with the Securities and Exchange Commission on February 27, 2024 Registration No. |
|
| February 27, 2024 |
SciSparc Ltd. Share Incentive Plan Exhibit 10.7 SciSparc Ltd. Share Incentive Plan Unless otherwise defined, terms used herein shall have the meaning ascribed to them in Section 2 hereof. 1. PURPOSE; TYPES OF AWARDS; CONSTRUCTION. 1.1. Purpose. The purpose of this 2023 Share Incentive Plan (as amended, this “Plan”) is to afford an incentive to Service Providers of SciSparc Ltd., an Israeli company (together with any successor corpo |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2024 (Report No.3) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address |
|
| February 27, 2024 |
FIRST AMENDMENT TO STANDBY EQUITY PURCHASE AGREEMENT Exhibit 10.22 FIRST AMENDMENT TO STANDBY EQUITY PURCHASE AGREEMENT This FIRST AMENDMENT TO THE STANDBY EQUITY PURCHASE AGREEMENT, dated as of February 26, 2024 (this “First Amendment”), is entered between SCISPARC LTD., a company incorporated in the State of Israel (“Company”), and YA II PN, LTD., a Cayman Islands exempt limited partnership (the “Investor”). PRELIMINARY STATEMENTS A. Reference is |
|
| February 20, 2024 |
Exhibit 99.1 SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds TEL AVIV, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central ner |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2024 (Report No.2) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address |
|
| February 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2024 Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal e |
|
| January 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2024 (Report No.3) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address o |
|
| January 29, 2024 |
Exhibit 99.1 SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder The clinical trial for SCI-210 will be conducted in Israel, after which the company aims to move forward with the commercialization process of SCI-210 first in the Israeli market TEL AVIV, Israel, Jan. 29, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPR |
|
| January 25, 2024 |
SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement Exhibit 99.1 SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement TEL AVIV, Israel, January 24, 2024 (GLOBE NEWSWIRE) – SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced that it has entered into a stand |
|
| January 25, 2024 |
STANDBY EQUITY PURCHASE AGREEMENT Exhibit 10.1 EXECUTION VERSION STANDBY EQUITY PURCHASE AGREEMENT THIS STANDBY EQUITY PURCHASE AGREEMENT (this “Agreement”) dated as of January 21, 2024 is made by and between YA II PN, LTD., a Cayman Islands exempt limited partnership (the “Investor”), and SCISPARC LTD., a company incorporated under the laws of the State of Israel (the “Company”). WHEREAS, the parties desire that, upon the terms a |
|
| January 25, 2024 |
Exhibit 4.1 THIS NOTE HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THIS NOTE HAS BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT O |
|
| January 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2024 (Report No. 2) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address |
|
| January 22, 2024 |
Exhibit 99.1 SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 million TEL AVIV, Israel, Jan. 19, 2024 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the cen |
|
| January 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2024 Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal ex |
|
| January 5, 2024 |
January 5, 2024 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| December 8, 2023 |
Exhibit 99.1 SciSparc Provides Updates Regarding the Non-Binding Letter of Intent to Acquire Leading Vehicle Importer Company in Israel TEL AVIV, Israel, Dec. 07, 2023 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system |
|
| December 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2023 Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address of principal e |
|
| November 28, 2023 |
Exhibit 99.1 SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment The pre- clinical trial conducted using the combined treatment of SciSparc’s proprietary CannAmide™ and Clearmind Medicine’s MEAI molecule TEL AVIV, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a sp |
|
| November 28, 2023 |
SciSparc Adopts Limited Duration Shareholder Rights Plan Exhibit 99.1 SciSparc Adopts Limited Duration Shareholder Rights Plan TEL AVIV, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its Board of Directors (the “Board”) has un |
|
| November 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2023 (Report No. 3) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address |
|
| November 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 SCISPARC LTD. (Exact name of registrant as specified in its charter) Israel Not applicable (State of incorporation or organization) (I.R.S. Employer Identification No.) 20 Raul Wallenberg Street, |
|
| November 28, 2023 |
SCISPARC LTD. VSTOCK TRANSFER, LLC Rights Agreement Dated as of November 28, 2023 TABLE OF CONTENTS Exhibit 4.1 Execution Copy SCISPARC LTD. AND VSTOCK TRANSFER, LLC Rights Agreement Dated as of November 28, 2023 TABLE OF CONTENTS 1. Definitions. 1 2. Appointment of Rights Agent. 4 3. Issue of Right Certificates. 4 4. Form of Right Certificates. 6 5. Countersignature and Registration. 6 6. Transfer, Split Up, Combination and Exchange of Right Certificates; Mutilated, Destroyed, Lost or Stolen Ri |
|
| November 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2023 (Report No. 4) Commission File Number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A Tel Aviv 6971916, Israel (Address |
|
| November 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2023 (Report No.2) Commission file number: 001-38041 SCISPARC LTD. (Translation of registrant’s name into English) 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel (Address |
|
| November 27, 2023 |
Exhibit 99.1 SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform MitoCareX Bio has met its second milestone as part of its joint venture agreement with the Company TEL AVIV, Israel, Nov. 27, 2023 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to |
|
| November 22, 2023 |
Exhibit 99.1 SciSparc Signs Non-Binding Letter of Intent to Merge with Leading Vehicle Importer Company in Israel SciSparc seeks to scale up revenues and will consider transferring its pharmaceutical activities to a separate legal entity and exploring the possibility of dividend distribution TEL AVIV, Israel, Nov. 22, 2023 (GLOBE NEWSWIRE) - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), |
